Aromics Biotech, a CataloniaBio & HealthTech member, and its Bermes project have been chosen to participate in the exhibition The fight against asbestos organised by Transports Metropolitans de Barcelona (TMB).
The exhibition will be on through mid-January at Espai Mercè Sala in the Diagonal metro station.
Aromics, led by Dr Carme Plasencia, is developing the drug NAX035 to treat malignant mesothelioma. Mesothelioma is the type of cancer caused by direct exposure to asbestos. It is aggressive, difficult to give a prognosis for and currently has very few therapeutic options.
Comments